Page Title
Clinical Trial Finder
Restore CFTR Function Completed with Results
Vertex Lumacaftor (VX-809) and Ivacaftor in Children with CF aged 6 to 11 years and have two copies of the delF508 CFTR mutation (Vertex VX13-809-011b)
This was an open-label study designed to look at the safety of lumacaftor in combination with ivacaftor (Orkambi®). This study was for younger children with CF who have two copies of the F508del CFTR mutation. There were two parts to this study. Part A was conducted to confirm that a dose of lumacaftor (200 mg) in combination with ivacaftor (250 mg) was safe and would result in potentially effective levels of the drug in the body. Part B was a 24 week study of the same dose given in Part A to evaluate the safety and efficacy of lumacaftor in combination with ivacaftor in children with CF.
Eligibility
See other primary eligibility criteria for more information.
-
Age:
6 Years to 11 Years -
Mutation(s):
Two Copies F508del -
FEV1% Predicted:
No FEV1 Limit
For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.
Other Primary Eligibility Criteria
Participants must be homozygous for the F508del cystic fibrosis transmembrane conductance regulator (CFTR) mutation
Study Results
-
What We Learned:
Lumacaftor in combination with ivacaftor was well tolerated at the doses tested. Treatment with lumacaftor in combination with ivacaftor resulted in significant improvements in sweat chloride, nutrition (BMI and weight), lung function (as measured by lung clearance index (LCI)) and quality of life (self-reported).
-
Primary Findings:
Effectiveness:
Part B of the study was conducted between February 2015 and April 2015. Of the 58 participants enrolled in Part B, 54 completed all 24 weeks of treatment with lumacaftor/ivacaftor. Two participants discontinued treatment due to drug related adverse events. One participant was enrolled but did not meet eligibility criteria and one participant voluntarily withdrew from the study. While the primary objective of the study was to evaluate the safety of lumacaftor in combination with ivacaftor, researchers also looked at absolute change in sweat chloride, BMI, weight and height, lung function (measured by FEV1 and LCI), as well as a self-reported quality of life questionnaire (CFQ-R). At the end of the 24-week treatment period, there was a significant reduction in sweat chloride (p<0.0001), increase in BMI and weight (p<0.0001), improvement in lung clearance index (P=0.0018), and improvement in the average response to the self-reported quality of life questionnaire (p=0.0085). Lung function as measured by FEV1 was not significantly improved by week 24.
Safety:
Lumacaftor in combination with ivacaftor at doses tested was generally well tolerated in this younger population, similar to what was observed in older individuals with CF. Laboratory tests of liver enzymes were significantly elevated in 19.3% of participants at some point during the study and resulted in study drug being interrupted or stopped for 5.3% of participants.
-
Citation:
Am J Respir Crit Care Med ;[Epub ahead of print]
For current information about the overall development status of this drug, please check the Drug Development Pipeline.
Study Design
-
Study Type: ?more info
Interventional -
Randomized Study: ?more info
No -
Placebo Controlled: ?more info
No -
Length of Participation:
27 weeks -
Number of Study Visits:
11
Additional Information
-
Phase: ?more info
Phase Three -
Study Sponsor: ?more info
Vertex -
Study Drugs:
Eligibility
See other primary eligibility criteria for more information.
-
Age:
6 Years to 11 Years -
Mutation(s):
Two Copies F508del -
FEV1% Predicted:
No FEV1 Limit
For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.
Other Primary Eligibility Criteria
Participants must be homozygous for the F508del cystic fibrosis transmembrane conductance regulator (CFTR) mutation
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More